Presentation is loading. Please wait.

Presentation is loading. Please wait.

Several microRNAs are differentially expressed in the glomeruli between different types of kidney disease. Several microRNAs are differentially expressed.

Published byByron Blake Modified over 6 years ago

Similar presentations

Presentation on theme: "Several microRNAs are differentially expressed in the glomeruli between different types of kidney disease. Several microRNAs are differentially expressed."— Presentation transcript:

1 Several microRNAs are differentially expressed in the glomeruli between different types of kidney disease. Several microRNAs are differentially expressed in the glomeruli between different types of kidney disease. (A) FSGS compared with DN. (B) MPGN compared with DN. (C) IgAN compared with FSGS. (D) MPGN compared with FSGS. (E) MPGN compared with IgAN. Log2 fold changes for microRNAs with FDR<0.05 are shown. Maria Angeles Baker et al. JASN 2017;28: ©2017 by American Society of Nephrology

Download ppt "Several microRNAs are differentially expressed in the glomeruli between different types of kidney disease. Several microRNAs are differentially expressed."

Similar presentations

Histomorphology in a case of mixed (cellular and humoral) acute kidney allograft rejection (patient 10). Histomorphology in a case of mixed (cellular and.

Histomorphology in a case of mixed (cellular and humoral) acute kidney allograft rejection (patient 10). Histomorphology in a case of mixed (cellular and.
Inhibition of ILK by QLT-0267 suppresses type I and type III collagen expression and ameliorates interstitial collagen deposition and renal fibrosis after.

Inhibition of ILK by QLT-0267 suppresses type I and type III collagen expression and ameliorates interstitial collagen deposition and renal fibrosis after.
Inhibition of ILK by QLT-0267 reduces β-catenin accumulation and inhibits Snail1 expression in obstructive nephropathy. Inhibition of ILK by QLT-0267 reduces.

Inhibition of ILK by QLT-0267 reduces β-catenin accumulation and inhibits Snail1 expression in obstructive nephropathy. Inhibition of ILK by QLT-0267 reduces.
TGF-β1 induces ILK activity in renal tubular epithelial cells.

TGF-β1 induces ILK activity in renal tubular epithelial cells.
Relationship between urinary TNF-α and RANTES excretion

Relationship between urinary TNF-α and RANTES excretion
Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.

Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.
Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6 expression. Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6.

Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6 expression. Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6.
Inhibition of ILK activity does not affect normal kidney structure and nephrin/ILK interaction in vivo. Inhibition of ILK activity does not affect normal.

Inhibition of ILK activity does not affect normal kidney structure and nephrin/ILK interaction in vivo. Inhibition of ILK activity does not affect normal.
Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.

Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.
Figure 1. Relationship between (A) total antioxidative activity (TAA) and endothelium-dependent vasodilation (EDV) (r = 0.41, P = 0.016), (B) lag phase.

Figure 1. Relationship between (A) total antioxidative activity (TAA) and endothelium-dependent vasodilation (EDV) (r = 0.41, P = 0.016), (B) lag phase.
Missense mutations in TNXB as a cause of VUR

Missense mutations in TNXB as a cause of VUR
Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.

Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.
Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF

Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF
Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.

Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.
Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.
T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.

T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.
Studies reporting the incident rate for all types of infections per 1000 patient days. Studies reporting the incident rate for all types of infections.

Studies reporting the incident rate for all types of infections per 1000 patient days. Studies reporting the incident rate for all types of infections.
Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration. Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration.

Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration. Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration.
INT-767 treatment prevents the increase in renal HIF and Glut1 expression and ER stress in diabetic DBA/2J mice. INT-767 treatment prevents the increase.

INT-767 treatment prevents the increase in renal HIF and Glut1 expression and ER stress in diabetic DBA/2J mice. INT-767 treatment prevents the increase.
INT-767 treatment prevents renal lipid accumulation in diabetic DBA/2J mice. INT-767 treatment prevents renal lipid accumulation in diabetic DBA/2J mice.

INT-767 treatment prevents renal lipid accumulation in diabetic DBA/2J mice. INT-767 treatment prevents renal lipid accumulation in diabetic DBA/2J mice.

Similar presentations

Ads by Google